Changes in Hong Kong stocks | Yuanda Pharmaceutical (00512) rose more than 3% in the intraday period, the innovative Chinese medicine drug GPN01360 reached the end of the domestic phase II clinical trial

The Zhitong Finance App learned that Yuanda Pharmaceutical (00512) rose more than 3% in the intraday period. As of press release, it had risen 2.59% to HK$8.32, with a turnover of HK$33.3737 million.

According to the news, Yuanda Pharmaceutical recently announced that the phase II clinical study of GPN01360, an innovative traditional Chinese medicine drug used to treat depression, has reached a clinical end in China. According to reports, GPN01360 is a Class 1.1 innovative traditional Chinese medicine for the treatment of depression (liver depression and spleen deficiency). It is based on the ancient classic prescription “Xiaoyao San” and optimized through modern pharmacology and clinical research screening. The prescription consists of 12 traditional Chinese medicines such as chaihu, tulip, and Buddha's hand, which have the effects of relieving the liver and spleen and relieving the mind.

Yuanda Pharmaceutical said that positive clinical research data has laid the foundation for subsequent research and development of GPN01360, and is expected to solve the problem of poor patient adherence due to side effects of existing Western medicines, thereby improving the sustainability and effectiveness of long-term treatment and bringing new solutions to improve the clinical cure rate of depression. At the same time, GPN01360 will also provide strong evidence-based medical evidence for traditional Chinese medicine to treat mental disorders such as depression, and verify the unique advantages and scientific value of proprietary Chinese medicine.